Correction: Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer
Shiqi Li(University of Science and Technology of China), Liping Xie(First Affiliated Hospital Zhejiang University), Jian Wu(Sun Yat-sen University), Xianglai Xu(Fudan University), Shuai Meng(Capital Medical University), Zhenghui Hu(First Affiliated Hospital Zhejiang University), Alin Ji(Zhejiang Provincial People's Hospital), Xiao Wang(Qingdao University), Hong Chen(Zhejiang University), Ben Liu(Zhejiang Cancer Hospital), Yi Zhu(Jiangsu University), Wei Wang(Capital Medical University), Zhen Liang(Shandong University), Xin Xu(Dalian Medical University), Xiangyi Zheng(Tianjin University), Yeqing Mao(First Affiliated Hospital Zhejiang University), Yiwei Lin(First Affiliated Hospital Zhejiang University)
Cited by 2
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276